fluorouracil has been researched along with Chromosomal Translocation in 7 studies
Fluorouracil: A pyrimidine analog that is an antineoplastic antimetabolite. It interferes with DNA synthesis by blocking the THYMIDYLATE SYNTHETASE conversion of deoxyuridylic acid to thymidylic acid.
5-fluorouracil : A nucleobase analogue that is uracil in which the hydrogen at position 5 is replaced by fluorine. It is an antineoplastic agent which acts as an antimetabolite - following conversion to the active deoxynucleotide, it inhibits DNA synthesis (by blocking the conversion of deoxyuridylic acid to thymidylic acid by the cellular enzyme thymidylate synthetase) and so slows tumour growth.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Forty-six patients with cT4b esophageal cancer, including borderline cT4b lesions, were eligible." | 5.72 | Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil. ( Ihara, K; Kikuchi, M; Kojima, K; Kubo, T; Morita, S; Muroi, H; Nakagawa, M; Nakajima, M; Nakamura, T; Takise, S; Yamaguchi, S, 2022) |
| "We report a breast cancer patient who developed acute myeloid leukemia (AML) one year following her adjuvant chemotherapy consisting of cyclophosphamide, adriamycin and 5-fluorouracil." | 3.73 | t(8;16) AML developed subsequent to breast cancer therapy. ( Akçali, Z; Boğa, S; DemIrhan, B; Karakuş, S; Sahin, FI; Yilmaz, Z, 2006) |
| "Forty-six patients with cT4b esophageal cancer, including borderline cT4b lesions, were eligible." | 1.72 | Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil. ( Ihara, K; Kikuchi, M; Kojima, K; Kubo, T; Morita, S; Muroi, H; Nakagawa, M; Nakajima, M; Nakamura, T; Takise, S; Yamaguchi, S, 2022) |
| "A 60-yr-old woman with breast cancer underwent breast-conserving surgery followed by 6 cycles of adjuvant chemotherapy (cyclophosphamide, epirubicin, and fluorouracil) and radiation therapy (dose, 5,040 cGy to the left breast and a 1,000 cGy boost to the tumor bed)." | 1.36 | A case of therapy-related ALL with MLL gene rearrangement following treatment of breast cancer. ( Cho, J; Hur, M; Lee, CH; Lee, HG; Moon, HW; Yun, YM, 2010) |
| "Melphalan (MEL) was the only drug used in single-drug chemotherapy." | 1.29 | Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants. ( Friberg, LG; Granberg, S; Islam, MQ; Köpf, I; Levan, A; Levan, G, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (14.29) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| Authors | Studies |
|---|---|
| Nakajima, M | 1 |
| Muroi, H | 1 |
| Kikuchi, M | 1 |
| Kubo, T | 1 |
| Takise, S | 1 |
| Ihara, K | 1 |
| Nakagawa, M | 1 |
| Morita, S | 1 |
| Nakamura, T | 1 |
| Yamaguchi, S | 1 |
| Kojima, K | 1 |
| Cho, J | 1 |
| Hur, M | 1 |
| Moon, HW | 1 |
| Yun, YM | 1 |
| Lee, CH | 1 |
| Lee, HG | 1 |
| Damodaran, S | 1 |
| Bellavia, T | 1 |
| Sait, SN | 1 |
| Wang, ES | 1 |
| Wetzler, M | 1 |
| Khushalani, NI | 1 |
| Lee, KC | 1 |
| Hamstra, DA | 1 |
| Bullarayasamudram, S | 1 |
| Bhojani, MS | 1 |
| Moffat, BA | 1 |
| Dornfeld, KJ | 1 |
| Ross, BD | 1 |
| Rehemtulla, A | 1 |
| Sahin, FI | 1 |
| Yilmaz, Z | 1 |
| Karakuş, S | 1 |
| Boğa, S | 1 |
| Akçali, Z | 1 |
| DemIrhan, B | 1 |
| Islam, MQ | 1 |
| Köpf, I | 1 |
| Levan, A | 1 |
| Granberg, S | 1 |
| Friberg, LG | 1 |
| Levan, G | 1 |
| Hao, SX | 1 |
| Ren, R | 1 |
7 other studies available for fluorouracil and Chromosomal Translocation
| Article | Year |
|---|---|
Strategy Treatment of cT4b Esophageal Squamous Cell Carcinoma Using Docetaxel, Cisplatin, and 5-Fluorouracil.
Topics: Cisplatin; Docetaxel; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Fluorouracil; Humans | 2022 |
A case of therapy-related ALL with MLL gene rearrangement following treatment of breast cancer.
Topics: Antibiotics, Antineoplastic; Blood Cell Count; Bone Marrow; Breast Neoplasms; Chemotherapy, Adjuvant | 2010 |
Acute myeloid leukemia secondary to oxaliplatin treatment for esophageal cancer.
Topics: Abnormal Karyotype; Adenocarcinoma; Antineoplastic Agents; Capecitabine; Clinical Trials, Phase II a | 2012 |
Fusion of the HSV-1 tegument protein vp22 to cytosine deaminase confers enhanced bystander effect and increased therapeutic benefit.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Bystander Effect; Cell Line; Cytosine Deamin | 2006 |
t(8;16) AML developed subsequent to breast cancer therapy.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone M | 2006 |
Cytogenetic findings in 111 ovarian cancer patients: therapy-related chromosome aberrations and heterochromatic variants.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Chil | 1993 |
Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder.
Topics: Animals; Antimetabolites, Antineoplastic; B-Lymphocytes; Base Sequence; Bone Marrow Transplantation; | 2000 |